Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

This study extended lipoprotein(a)‘s causal reach from the coronary arteries to the aortic valve — establishing it as a cause of calcific aortic stenosis, a disease previously seen as simple wear-and-tear.

In nearly 78,000 people from the general population, elevated Lp(a) showed a clear dose-dependent association with aortic stenosis: levels above the 95th percentile (over 90 mg/dL) conferred roughly threefold risk. The genetic analysis sealed the causal inference — carriers of LPA risk variants had correspondingly elevated risk, and the genetic and observational estimates agreed closely, the signature of causation.

The clinical implication is significant: aortic stenosis, like coronary disease, is partly driven by an inherited, measurable, and potentially treatable lipoprotein — opening the prospect that future Lp(a)-lowering therapy might slow or prevent valve disease, for which no medical treatment currently exists.

We rate the evidence strong, with high clinical significance. A large general-population study combining observation and genetics, it is a landmark in recognizing Lp(a) as a causal driver of valvular as well as arterial disease.